Neurizon Therapeutics Limited has released a press release.
Epichem new CEO and Board additions
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Appendix 3B & s708 Notice
- PharmAust Receives Pre-Approval for R&D Tax Rebates
- Epichem Export Business Receives Important WA State Awards
- PharmAust Raises $2.4m in Placement
- Agreement with Uni of Melbourne U-Vet for Phase II Dog Trial
Later from Neurizon Therapeutics
- AGM Presentation
- Progress in Recruitment for Phase II Trial in Dogs
- Presentation - Pitt Street Research Life Sciences Conference
- Expanded Site Recruitment for Phase II MPL Dog Cancer Trial
- Epichem client gives notice to end contract in February 2020
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics